Investor Presentation

37 B-cell function Investor presentation First six months of 2022 Diabetes is a chronic disease requiring treatment intensification over time Diet and exercise OAD GLP-1 Distribution of patients and value across treatment classes 45% 4% 14% 19% 2% 10% 28% Insulin 9% 8% 28% 34% Time Patients Insulin GLP-1 Inj. Value Oral GLP-1 SGLT-2i DPP-4i Trad. OAD Note: Patient distribution across treatment classes is indicative and based on data for USA, Germany, France. Other OADS cover: metformin, sulfonylurea, thiazolidinediones. Source: IQVIA PharMetrix claims data, IQVIA disease analyser, IQVIA MIDAS; value figures based on IQVIA MAT, May 2022 OAD: Oral anti-diabetic Novo NordiskⓇ

View entire presentation